All Posts
July 10, 2026
Patient's Guide: China's Top 10 General Surgery Hospitals 2023 (Fudan Rankings)
China is a global leader in general surgery: ranked 2nd worldwide in robotic surgery volume, pioneering minimally invasive techniques and integrating AI into surgical planning.
Read more →July 09, 2026
Step-by-Step Process for Cancer Treatment in China with HomeMed
A step-by-step guide to travelling to China for oncology treatment: file consultation, visa, invitation letter, translation, interpretation and hospital accompaniment.
Read more →July 09, 2026
Base Editing Therapy: A New Direction for China's One-Time Cure of Thalassemia
China has over 30 million thalassemia gene carriers. Base editing therapy by Children's Hospital of Fudan University and Prof. Chen Jia's team opens the hope of a one-time cure.
Read more →July 08, 2026
Durvalumab + Tremelimumab — Dual Immunotherapy for Hepatocellular Carcinoma (HCC)
Combining Durvalumab (PD-L1 inhibitor) and Tremelimumab (CTLA-4 inhibitor) creates dual immunotherapy, opening a new option for advanced hepatocellular carcinoma patients.
Read more →July 08, 2026
6 Billion Investment & Global Benchmarking: Arion Hospital International Medical's Talent Strategy
Backed by roughly 6 billion yuan from ByteDance, Beijing's Arion Hospital International Medical Complex is reshaping China's private healthcare, with a talent strategy for 2029.
Read more →July 07, 2026
Cetuximab (Erbitux) — Anti-EGFR Monoclonal Antibody for Colorectal Cancer
Cetuximab targets EGFR, inhibiting tumour cell proliferation in KRAS/NRAS wild-type colorectal cancer. Learn about its role and indications in treatment in China.
Read more →July 07, 2026
Proton Therapy: A Mature and Safe Technology
Proton therapy uses high-energy proton beams with the Bragg Peak effect to concentrate the radiation dose on the tumor while minimizing damage to surrounding healthy tissue.
Read more →July 06, 2026
Ipilimumab — CTLA-4 Immune Checkpoint Inhibitor in Cancer Treatment
Ipilimumab inhibits CTLA-4, amplifying the anti-cancer immune response. Commonly combined with Nivolumab for optimal outcomes.
Read more →July 06, 2026
Hospital Guide: United Family Healthcare (UFH) — Your Trusted Partner for International-Standard Care in China
United Family Healthcare (UFH) is China's most established and comprehensive international healthcare provider, with all hospitals JCI-accredited and English-speaking staff.
Read more →July 05, 2026
Pertuzumab (Perjeta) — Combination Monoclonal Antibody for HER2+ Breast Cancer
Pertuzumab combined with Trastuzumab creates dual HER2 blockade, improving outcomes in HER2-positive breast cancer. For reference.
Read more →July 05, 2026
Minimally Invasive Surgery for Lung Cancer: A Comprehensive Overview
For early-stage lung cancer, surgical resection is preferred. Thoracoscopic surgery needs only a 3 cm incision, 95% of patients avoid transfusion, and recovery is faster.
Read more →July 04, 2026
Osimertinib (Tagrisso) — 3rd-Generation TKI for EGFR-Mutated Lung Cancer
Osimertinib is a 3rd-generation tyrosine kinase inhibitor (TKI) targeting EGFR mutations, including the resistance mutation T790M. Widely used in lung cancer treatment in China.
Read more →